Durvalumab with cisplatin and etoposide
WebJan 17, 2024 · Day 1: Durvalumab 1,500mg IV over 60 minutes, followed by: Day 1: Carboplatin AUC 5-6 IV over 30 minutes Days 1-3: Etoposide 80-100mg/m 2 IV over 60 … WebFeb 28, 2024 · The EP regimen (etoposide plus cisplatin), in particular, ... CASPIAN, aimed to explore the efficacy of the anti–PD-L1 antibody durvalumab and the anti–CTLA-4 antibody tremelimumab combined with chemotherapy in the first-line treatment of patients with ES-SCLC. The study included patients with untreated ES-SCLC who were randomly …
Durvalumab with cisplatin and etoposide
Did you know?
WebNov 23, 2024 · Of the 531 patients who did receive treatment, 416 (78%) received carboplatin and 132 (25%) received cisplatin. In the durvalumab plus … WebOct 26, 2024 · Durvalumab group: Cisplatin (75 mg/m² (BSA) D1#) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 1.8-2 Gy/d with start at latest at beginning of cycle 3, ideally during cycle 1) and additional Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles according to …
WebMar 16, 2024 · Cisplatin + Etoposide (Category 1) 108,dd. Day 1: Cisplatin 100mg/m 2 IV over 2 hours. Days 1-3: Etoposide 100mg/m 2 IV over 60 minutes daily. Repeat cycle every 3 weeks for 4-6 cycles. Cisplatin ... WebDec 4, 2024 · First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide) showed a significant improvement in overall survival versus …
WebApr 11, 2024 · Two phase 3 trials evaluated the addition of programmed cell death-ligand 1 (PD-L1) inhibitor atezolizumab (IMpower133) (5, 6) or durvalumab (CASPIAN) (7, 8) to first-line chemotherapy (etoposide and cisplatin [EP]) followed by maintenance PD-L1 inhibitor in patients with ES-SCLC, and showed a significant improvement in overall survival (OS ... WebNov 4, 2024 · Eligible patients will receive durvalumab plus carboplatin and etoposide every 3 to 4 weeks for up to 4 cycles, followed by durvalumab every 4 weeks until …
WebApr 16, 2024 · In terms of trial CASPIAN, patients were assigned to receive durvalumab plus etoposide-cisplatin (EP) or etoposide-carboplatin (EC) regimen. Patients received up to 4 cycles of chemotherapy plus durvalumab 1500 mg followed by maintenance durvalumab 1500 mg every 4 weeks or placebo. [7]
WebOct 31, 2024 · CASPIAN, which is being conducted at 209 sites across 23 countries, was funded by AstraZeneca, the maker of durvalumab. Durvalumab is already being used as standard therapy for patients with … flamingo sweatpantsWebApr 7, 2024 · Background In the phase 3 CASPIAN study (NCT03043872), first-line durvalumab plus etoposide and cisplatin or carboplatin (EP) significantly improved OS versus EP alone in patients with extensive-stage (ES)-SCLC (HR 0.73 [95% CI 0.59–0.91; p = 0.0047]). Here we report results for a preplanned subgroup analysis of patients … flamingo swimsuitWebNational Center for Biotechnology Information can protein be badWebMar 30, 2024 · Mar 30, 2024. Gina Columbus. The FDA has approved durvalumab for the first-line treatment of adult patients with extensive-stage small cell lung cancer for use in combination with standard-of-care ... can protein burn fatWebDurvalumab injection comes as a liquid to be injected into a vein over 60 minutes by a doctor or nurse in a hospital or medical facility. It is usually injected once every 2 weeks, … can protein cause headachesWebMar 9, 2024 · In CASPIAN, patients receiving durvalumab with etoposide and either cisplatin or carboplatin also demonstrated improved OS (HR, 0.73; 95% CI, 0.59–0.91; … flamingo switchWebDec 5, 2024 · Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung … flamingo tank top chaser